Alterola Biotech, Inc.
ABTI
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 88.82% | 30.93% | 11.90% | -62.51% | -81.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.01% | 21.72% | 3.30% | -60.13% | -80.14% |
| Operating Income | -75.01% | -21.72% | -3.30% | 60.13% | 80.14% |
| Income Before Tax | -118.95% | -34.71% | -0.89% | 48.19% | 81.50% |
| Income Tax Expenses | -100.00% | -- | -- | 392.30% | 200.00% |
| Earnings from Continuing Operations | -104.57% | -34.70% | -0.89% | 41.19% | 79.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.18% | -34.70% | -0.89% | 41.19% | 79.94% |
| EBIT | -75.01% | -21.72% | -3.30% | 60.13% | 80.14% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -15.79% | 13.64% | 23.08% | 55.56% | 79.35% |
| Normalized Basic EPS | 0.00% | 33.33% | 25.00% | 67.50% | 79.66% |
| EPS Diluted | -15.79% | 13.64% | 23.08% | 55.56% | 79.35% |
| Normalized Diluted EPS | 0.00% | 33.33% | 25.00% | 67.50% | 79.66% |
| Average Basic Shares Outstanding | 71.46% | 50.42% | 31.32% | 14.57% | 1.44% |
| Average Diluted Shares Outstanding | 71.46% | 50.42% | 31.32% | 14.57% | 1.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |